BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Sponsor: City of Hope Medical Center
Listed as NCT04690595, this PHASE1 trial focuses on Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and remains ongoing. Sponsored by City of Hope Medical Center, it has been updated 19 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
19 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Sep 2024 — Aug 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 14 earlier versions
-
Mar 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
May 2023 — Mar 2024 [monthly]
Recruiting PHASE1
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Mar 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Dec 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Nov 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- City of Hope Medical Center
- PeproMene Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .